GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Frequently asked questions
What sector does GH Research PLC (GHRS) operate in?
GH Research PLC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is GH Research PLC (GHRS) current stock price?
As of the latest data, GH Research PLC stock price is $19.18, with a previous close of $18.07. GH Research PLC gained $1.11 in the last trading session, representing a 6.14% increase.
What is GH Research PLC (GHRS) current market capitalization?
GH Research PLC market cap is approximately 1.32 billion.
What is GH Research PLC (GHRS) Earnings Per Share (EPS)?
The trailing EPS is -$1.04, and the forward EPS is -$1.85.
What is GH Research PLC (GHRS) EBITDA?
GH Research PLC EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -15.05 million.
Does GH Research PLC (GHRS) pay dividends?
No. GH Research PLC does not pay a dividend.
When is GH Research PLC (GHRS) next earnings report?
GH Research PLC is expected to release its next earnings report on September 30, 2026.
What is GH Research PLC (GHRS) beta (volatility) score?
GH Research PLC has a beta of 1.325, suggesting it is more volatile than the market.
